Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

This study will evaluate the efficacy and safety of irinotecan liposome(II) in combination with Ivonescimab as second line treatment for SCLC.

PHASE2

The Second Affiliated Hospital of Dalian Medical University

Shengjing Hospital